血浆ctDNA极早期反应预测非小细胞肺癌纳武利尤单抗疗效
本研究纳入14例接受纳武利尤单抗治疗的非小细胞肺癌患者,评估启动治疗后早期循环肿瘤DNA(ctDNA)水平变化能否预测治疗结局。结果显示高肿瘤体积患者系列血浆中ctDNA检出更频繁(p=0.02),以2周为时间点时代表突变等位基因频率变化与缓解状态100%一致。
要点
- 高肿瘤体积患者系列血浆样本中ctDNA检出更频繁(p=0.02)。
- ctDNA等位基因频率下降与持久良好缓解高度对应。
- 以2周为时间点,代表突变变化与缓解状态100%一致。
核心结论
- 在高肿瘤体积患者中,经肿瘤组织验证的血浆ctDNA分析提示可在2周内预测纳武利尤单抗的持久良好缓解。
研究设计与样本
- 研究纳入2016年2月1日至9月30日接受纳武利尤单抗治疗的14例患者,评估启动治疗后ctDNA早期反应能否预测治疗结局。
- 仅将经肿瘤组织分析确认的体细胞突变定义为ctDNA。
主要发现
- 14例患者中6例为缓解者、8例为非缓解者。
- 高肿瘤体积(TV)患者系列血浆样本中ctDNA检出更频繁(p=0.02)。
- 7例检出ctDNA;基线与系列ctDNA分析显示ctDNA等位基因频率(AF)下降与持久良好缓解高度对应。
- 以「2周」为临床显著时间点,各例代表突变(定义为基线AF最高者之一)的变化与缓解状态显示100%一致。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy has become a treatment option for lung cancer. The utility of nivolumab as second-line treatment for non-small cell lung cancer has been proven, but predictive biomarkers influencing its efficacy remain unknown. METHODS: This study involved 14 patients who were treated with nivolumab from February 1 to September 30, 2016. The early response of the level of circulating tumour DNA (ctDNA) after starting nivolumab was evaluated to ascertain whether it could predict treatment outcome. RESULTS: Of the 14 patients, six were responders and eight were non-responders. DNA was analysed in both tumour tissue and plasma samples. Only somatic mutations confirmed by analysis of tumour tissue were defined as ctDNA. ctDNA was detected more often in the serial plasma samples of patients with high tumour volume (TV) (p = 0.02). ctDNA was detected in seven cases; basal and serial ctDNA analysis revealed that a decrease in allelic frequency (AF) of ctDNA showed high-level correspondence with a good durable response. When "2 weeks" was set as a clinically significant time point, changes in representative mutations of each case, defined as one of the highest baseline AF, showed 100% concordance with the response. CONCLUSIONS: In patients with high TV, plasma analysis of ctDNA, as validated by tumour tissue, suggested that a durable good response to nivolumab could be predicted within 2 weeks.
引用
- Iijima Y, Hirotsu Y, Amemiya K, et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. Eur J Cancer. 2017. PMID: 29078173. doi:10.1016/j.ejca.2017.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。